Matrix metalloproteinases as valid clinical targets.
Fingleton, Barbara
Matrix metalloproteinases as valid clinical targets. [electronic resource] - Current pharmaceutical design 2007 - 333-46 p. digital
Publication Type: Journal Article; Review
1873-4286
10.2174/138161207779313551 doi
Animals
Arthritis--drug therapy
Atherosclerosis--drug therapy
Drug Design
Extracellular Matrix Proteins--metabolism
Eye Diseases--drug therapy
Heart Rupture, Post-Infarction--drug therapy
Humans
Hypertrophy, Left Ventricular--drug therapy
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases--metabolism
Myocardial Infarction--drug therapy
Neoplasms--drug therapy
Protease Inhibitors--pharmacology
Pulmonary Disease, Chronic Obstructive--drug therapy
Respiratory Distress Syndrome--drug therapy
Skin Diseases--drug therapy
Stroke--drug therapy
Vascular Diseases--drug therapy
Matrix metalloproteinases as valid clinical targets. [electronic resource] - Current pharmaceutical design 2007 - 333-46 p. digital
Publication Type: Journal Article; Review
1873-4286
10.2174/138161207779313551 doi
Animals
Arthritis--drug therapy
Atherosclerosis--drug therapy
Drug Design
Extracellular Matrix Proteins--metabolism
Eye Diseases--drug therapy
Heart Rupture, Post-Infarction--drug therapy
Humans
Hypertrophy, Left Ventricular--drug therapy
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases--metabolism
Myocardial Infarction--drug therapy
Neoplasms--drug therapy
Protease Inhibitors--pharmacology
Pulmonary Disease, Chronic Obstructive--drug therapy
Respiratory Distress Syndrome--drug therapy
Skin Diseases--drug therapy
Stroke--drug therapy
Vascular Diseases--drug therapy